Document:

EXHIBIT 10.2

  R E S T R I C T I O N A G R E
      E M E N T

    Non-transferable 

    GRANT TO 

    ______________________

    (“Grantee”) 

  

by Premiere Global Services, Inc. (the “Company”) of

shares of its common stock, $0.01 par value (the “Shares”) 

pursuant to and subject to the provisions of the Premiere Global Services, Inc. 2000 Directors Stock Plan, as amended (the “Plan”) and to the terms and conditions set forth on the following page (the
“Terms and Conditions”).  By accepting the Shares, Grantee shall be deemed to have agreed to the terms and conditions set forth in this Agreement and the Plan. 

      The Shares shall be fully vested as of the date of grant.

      IN WITNESS WHEREOF, Premiere Global Services, Inc., acting by and through its duly authorized officers, has caused this Agreement to be executed as of the date of grant. 

	 	
PREMIERE GLOBAL SERVICES, INC. 
	
	 	
By: 
______________________________	
	 	 
	
	 	
           Its: Authorized Officer 
	    

	 	 
	 	
Date of Grant: 
_______________________	
	 	 
	 	
Accepted by Grantee: 
_________________	

TERMS AND CONDITIONS

1. Grant of Shares. The Company hereby grants to the Grantee named on page 1 hereof (“Grantee”), subject to the restrictions
and the other terms and conditions set forth in the Plan and in this restriction agreement (this “Agreement”), the number of shares indicated on page 1 hereof of the Company’s $0.01 par value common stock (the “Shares”).
Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Plan. 

2. Restrictions. The Shares are fully vested as of the date of grant and are not subject to any restrictions.

4. Delivery of Shares.  The Shares will be registered in the name of Grantee as of the date of grant.

Stock certificates for the Shares shall be delivered to Grantee or Grantee’s designee upon request of Grantee, but delivery may be postponed for such period as may be required for the Company with reasonable
diligence to comply, if deemed advisable by the Company, with registration requirements under the 1933 Act, listing requirements under the rules of any stock exchange or the New York Stock Exchange, and requirements under any other law or regulation
applicable to the issuance or transfer of the Shares. 

5. Voting and Dividend Rights. Grantee, as beneficial owner of the Shares, shall have full voting and dividend rights with respect to
the Shares.

6. Changes in Capital Structure. The provisions of the Plan shall apply in the case of a change in the capital structure of the
Company.

8. Amendment.  The Committee may amend, modify or terminate this Agreement without approval of Grantee; provided, however, that such
amendment, modification or termination shall not, without Grantee’s consent, reduce or diminish the value of this award determined as if it had been fully vested on the date of such amendment or termination. 

9. Plan Controls.  The terms contained in the Plan are incorporated into and made a part of this Agreement and this Agreement shall be
governed by and construed in accordance with the Plan. In the event of any actual or alleged conflict between the provisions of the Plan and the provisions of this Agreement, the provisions of the Plan shall be controlling and determinative.

10. Severability.  If any one or more of the provisions contained in this Agreement is deemed to be invalid, illegal or unenforceable,
the other provisions of this Agreement will be construed and enforced as if the invalid, illegal or unenforceable provision had never been included. 

11. Notice. Notices and communications under this Agreement must be in writing and either personally delivered or sent by registered or
certified United States mail, return receipt requested, postage prepaid. Notices to the Company must be addressed to: 

  Premiere Global Services, Inc. 

    3399 Peachtree Road, N.E. 

    The Lenox Building, Suite 700 

    Atlanta, Georgia 30326 

    Attn: Director, Stock Plan Management

  

or any other address designated by the Company in a written notice to Grantee. Notices to Grantee will be directed to the address of Grantee then currently on file with the Company, or at any other address given by
Grantee in a written notice to the Company.10Q Q3 2006 EXHIBIT 4.3

 

Exhibit 4.3 

PHARMACYCLICS, INC.

STOCK PURCHASE AGREEMENT

This Stock Purchase Agreement (this "Agreement") is entered
into by and between Pharmacyclics, Inc., a Delaware corporation (the
"Company"), and Applera Corporation, a Delaware corporation, by
and through the Celera Genomics Group ("Celera"), as of
April 7, 2006. 

RECITALS

WHEREAS, the Company and Celera have entered into that certain Assignment
Agreement dated April 7, 2006 (the "Assignment
Agreement"), pursuant to which the Company has agreed to issue to
Celera, subject to the terms and conditions hereof, between five hundred
thousand (500,000) and one million (1,000,000) shares (the
"Shares") of the Company's common stock, par value $0.0001 per
share (the "Common Stock"), in consideration of the assignment
by Celera to the Company of certain therapeutic products, methods, compounds and
related information, patents and other proprietary technology (the
"Celera Assets"), as described in the Assignment Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants and obligations set
forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Company and Celera agree as
follows:

	Issuance of Common Stock.  

	At the Closing (as defined below), the Company will issue to Celera, and
Celera will acquire from the Company, upon the terms and conditions hereinafter
set forth, the Shares, which shall be registered in the name of Applera
Corporation. 
	The execution of the Assignment Agreement and the assignment of the Celera
Assets described therein shall constitute full payment of the purchase price for
the Shares by Celera.  Celera shall not be obligated to pay any other
consideration to the Company in respect of the Shares.  The number of Shares to
be issued at the Closing shall be calculated as follows:

(a)If the Average Trading Price (as defined below) is less than [
*** ], then the number of Shares issued at the Closing shall be equal to one
million (1,000,000); and 

(b)If the Average Trading Price is [ *** ] or more, then the
number of shares issued at the Closing shall be an amount equal to [ *** ]
divided by the Average Trading Price; 

provided, however, that in no event shall the number of Shares
issued at the Closing be less than five hundred thousand (500,000) shares.
"Average Trading Price" shall mean the price equal to the
average of the closing per share price of the Common Stock as reported on The
Nasdaq National Market over the [ *** ] trading period ending on [ ***
]. 

	Closing, Delivery.

	The closing of the issuance of the Shares shall take place at the offices of
Latham & Watkins LLP, 135 Commonwealth Drive, Menlo Park, California, at
10:00 a.m., no later than five (5) business days after [ *** ], or at
such other time and place as the parties shall agree upon (which time and place
are designated as the "Closing"). 
	At the Closing, the Company will deliver to Celera a certificate registered
in the name of Applera Corporation for the Shares. 

 

	The Company's Representations and Warranties.  The Company represents
and warrants to Celera as follows:

	Organization, Good Standing and Qualification.  The Company is a
corporation duly organized, validly existing and in good standing under the laws
of the State of Delaware and has all requisite corporate power and authority to
carry on its business as now conducted and as presently proposed to be
conducted.  The Company is duly qualified to transact business and is in good
standing as a foreign corporation in each jurisdiction in which the failure to
so qualify would have a material adverse effect on its business or properties.

	Authorization.  The Company has full right, power and authority to
enter into this Agreement and to consummate the transactions contemplated
hereby.  All corporate action on the part of Company, its officers, directors
and stockholders necessary for the authorization, execution and delivery of this
Agreement, the performance of all obligations of Company hereunder and the
authorization, issuance and delivery of the Shares has been taken or will be
taken prior to the Closing.  This Agreement constitutes a valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer,
liquidation or similar laws relating to, or affecting generally, the enforcement
of creditor's rights and remedies or by other equitable principals of general
application from time to time in effect, or with respect to indemnity, as may be
limited by state or federal securities laws or the public policy underlying such
laws. 
	Valid Issuance of Securities; Private Offering.  The Shares, when
issued, sold and delivered in accordance with the terms hereof for the
consideration expressed herein, will be duly and validly authorized and issued,
fully paid and nonassessable and free of restrictions on transfer and all other
liens and encumbrances, other than restrictions on transfer under this Agreement
and applicable state and federal securities laws.  Subject to the accuracy of
Celera's representations set forth in Section 4, the offer, sale and issuance of
the Shares in accordance with the terms of this Agreement is exempt from (i) the
registration requirements of the Securities Act of 1933 (the "Securities
Act") and (ii) applicable state registration or qualification
requirements, in each case, other than those with which the Company has complied
or will comply prior to the applicable compliance deadline (the
"Securities Law Requirements").  The Company has not engaged in
any "general solicitation", as defined in Regulation D promulgated
under the Securities Act, with respect to the Shares. 
	Legal Proceedings and Orders; No Conflicts.  There is no action,
suit, proceeding or investigation pending or threatened against the Company that
questions the validity of this Agreement or the right of the Company to enter
into this Agreement or to consummate the transactions contemplated hereby, nor
is the Company aware of any basis for any of the forgoing.  The Company is
neither a party nor subject to the provisions of any order, writ, injunction,
judgment or decree of any court or government agency or instrumentality that
would affect the ability of the Company to enter into this Agreement or to
consummate the transactions contemplated hereby.  The performance by the Company of this Agreement and the
transactions contemplated herein do not violate or constitute a default under
any contract or other agreement or instrument to which the Company is a party.

	Consents.  Except for Permits (as defined below), the absence
of which either individually or in the aggregate would not have a material
adverse effect on the Company, and except for compliance with the Securities
Laws Requirements as described above, all permits, consents, approvals, orders,
authorizations of, or declarations to (collectively, "Permits")
or filings with any federal, state, local or foreign court, governmental or
regulatory authority, or other person (including third party consents) required
on the part of the Company in connection with the execution, delivery or
performance of this Agreement and the consummation of the transactions
contemplated herein have been obtained or will be obtained prior to the Closing,
and will be effective as of the Closing. 
	Disclosure.  The information contained in each of the documents filed
or furnished by the Company with the Securities and Exchange Commission (the
"SEC") pursuant to the reporting requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act") since
June 30, 2005, as of the respective filing date of each such document, did not
contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein in
light of the circumstances under which they were made not misleading.  Since
June 30, 2005, the Company has filed or furnished with the SEC all reports,
statements, and documents as and when required to be filed or furnished with the
SEC pursuant to the requirements of the Exchange Act. 

 

	Representation and Warranties of Celera.  Celera represents and
warrants to the Company as follows:

	Power and Authority.  This Agreement constitutes a valid and binding
obligation of Celera, enforceable against Celera in accordance with its terms,
except as such enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent transfer, liquidation or
similar laws relating to, or affecting generally, the enforcement of creditor's
rights and remedies or by other equitable principals of general application from
time to time in effect, or with respect to indemnity, as may be limited by state
or federal securities laws or the public policy underlying such laws.  Celera
further represents and warrants to the Company that Celera has full right, power
and authority to enter into this Agreement and to consummate the transactions
contemplated hereby and has taken all necessary action to authorize the
execution, delivery and performance of this Agreement. 
	Accredited Investor.  Celera: (i) is an "accredited
investor" as defined in Regulation D under the Securities Act and Celera
has the knowledge, sophistication and experience necessary to make, and is
qualified to make decisions with respect to, investments in shares presenting an
investment decision like that involved in the purchase of the Shares, including
investments in securities issued by the Company and investments in comparable
companies, and has requested, received, reviewed and considered all information
it deemed relevant in making an informed decision to purchase the Shares;
(ii)  is acquiring the Shares for its own account for investment only and
with no present intention of distributing any of such Shares or any arrangement
or understanding with any other persons regarding the distribution, sale or
transfer of such Shares; (iii) will not, directly or indirectly, offer, sell,
pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase
or otherwise acquire or take a pledge of) any Shares except in compliance with
the Securities Act, applicable state securities laws and the respective rules
and regulations promulgated thereunder; (iv)  (A) has had no position,
office or other material relationship within the past three years with the
Company and (B) neither it, nor any group of which it is a member or to which it
is related, beneficially owns (including the right to acquire or vote) any
securities of the Company; and (v) has, in connection with its decision to
acquire the Shares, had access to the Company's reports, forms and other
documents filed with the SEC pursuant to the Exchange Act.  Celera understands
that its acquisition of the Shares has not been registered under the Securities
Act or registered or qualified under any state securities law in reliance on
specific exemptions therefrom, which exemptions may depend upon, among other
things, the bona fide nature of Celera's investment intent as expressed herein.
Celera further understands that the Shares are "restricted securities" under
applicable federal and state securities laws and that, pursuant to these laws,
Celera must hold the Shares indefinitely unless they are registered under the
Securities Act, or an exemption from such registration requirements is
available. Celera acknowledges that, except as specifically provided for in this
Agreement, the Company has no obligation to register or qualify the Shares for
resale. Celera further acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements
including, but not limited to, the time and manner of sale, the holding period
for the Shares, and requirements relating to the Company which are outside of
Celera's control, and which the Company is under no obligation and may not be
able to satisfy. 
	Short Position.  Celera represents and warrants that, as of the date
of this Agreement it does not have a Short Position with respect to the Shares.
A "Short Position" shall mean a position resulting from a
"short sale" as such transaction is described in Rule 200 of
Regulation SHO promulgated under the Securities Exchange Act of 1934, as
amended. 
	Agreement to Vote Shares.  In all stockholder actions for so long as
Celera holds any of the Shares, Celera agrees to vote the Shares in the manner
recommended by the Company's Board of Directors. 
	Taxes.  Celera understands that nothing in this Agreement or any
other materials presented to Celera in connection with the purchase and sale of
the Shares constitutes legal, tax or investment advice.  Celera has consulted
such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of Shares.
Celera further agrees that it will be solely responsible for the withholding
and/or payment of any federal, state, or local taxes with respect to its
acquisition and holding of the Shares issued to it hereunder, and it will
indemnify and hold the Company harmless from all liability related to its tax
treatment as a holder of the Shares. 

 

	Lock-Up; Limitations on Transfer.  Celera agrees that, for a period
beginning on the date of hereof and ending on June 30, 2007, Celera shall not
offer, sell, contract to sell, pledge, grant any option to purchase, make any
short sale or otherwise dispose of any of the Shares or grant any option or
other rights to any person to acquire the Shares without the prior written
consent of the Company.  Celera covenants that, subject to other restrictions on
transfer set forth elsewhere in this Agreement, in no event shall it dispose of
any of the Shares (other than pursuant to Rule 144 under the Securities Act or
any similar or analogous rule or pursuant to the registration rights provisions
set forth in Section 7 hereof), unless and until (a) Celera shall have notified
the Company of the proposed disposition, and (b) if requested by the Company,
Celera shall have furnished the Company with an opinion of counsel (which may be
Celera's in-house counsel who is also an officer of Celera and who is
experienced and knowledgeable in securities laws transactions ("Celera's
In-House Counsel")) reasonably satisfactory in form and substance to
the Company and its counsel to the effect that (i) such disposition shall not
require registration under the Securities Act and (ii) appropriate action
necessary for compliance with the Securities Act and any applicable state, local
or foreign law has been taken. 

 

	Legends. 

	Celera acknowledges that until the Shares have been registered on an
effective registration statement or meet the condition specified in Section
6.1(b) below, the certificate or certificates representing the Shares shall bear
legends in substantially the following form (as well as any legends required by
applicable state and federal corporate and securities laws):

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A
VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.  NO SUCH SALE
OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT
RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

The Company shall promptly reissue a certificate or certificates without the
legend set forth above at the request of Celera if (a) the Shares have been
registered on an effective registration statement, or (b) Celera shall have
obtained an opinion of counsel (which may be Celera's In-House Counsel)
reasonably satisfactory in form and substance to the Company and its counsel to
the effect that (i) the securities proposed to be disposed of may lawfully be so
disposed of without registration, qualification, or legend, and (ii) any
appropriate action necessary to be taken by Celera for compliance with the
Securities Act and any applicable state, local or foreign law has been taken.

	Celera acknowledges that until the restrictions set forth in Section 5 above
have lapsed with respect to any Shares, the certificate or certificates
representing those Shares shall bear legends in substantially the following
form:

THE SECURITIES EVIDENCED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP
AGREEMENT  AND  MAY  NOT  BE  SOLD,  TRANSFERRED  OR ASSIGNED OTHER THAN IN
ACCORDANCE WITH THE TERMS OF THAT CERTAIN STOCK PURCHASE AGREEMENT, DATED APRIL
7, 2006 WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY.

At Celera's request, the Company shall promptly reissue a certificate or
certificates without the legend set forth above for any Shares as to which the
restrictions set forth in Section 5 above have lapsed. 

	Registration Rights. 

	 Resale Registration Statement.  The Company agrees to file with the
SEC a registration statement (the "Registration Statement"), on Form S-3
or any successor form, so as to permit a non-underwritten public offering and
resale of the Shares by Celera on a delayed or continuous basis under Rule 415
of the Securities Act.  The Company will use its commercially reasonable efforts
to cause the Registration Statement to be filed and declared effective under the
Securities Act no later than June 30, 2007.  The Company will prepare and file
with the SEC such amendments and supplements to the Registration Statement and
take all such other actions as may be necessary to keep the Registration
Statement effective for a period (the "Registration Period")
ending on the earliest of (a) the first date on which all of the Shares held by
Celera could be sold by Celera either (i) pursuant to Rule 144(k) under the
Securities Act (or any successor rule thereto) or (ii) in any three month period
pursuant to Rule 144 under the Securities Act (or any successor rule thereto);
(b) the date that all Shares held by Celera have been sold (I) pursuant to the
Registration Statement, (II) to or through a broker, dealer or underwriter in a
public distribution or a public securities transaction, and/or (III) in a
transaction exempt from the registration and prospectus delivery requirements of
the Securities Act under Section 4(1) thereof so that all transfer restrictions
and restrictive legends with respect thereto, if any, are removed upon the
consummation of such sale; and (c) the second anniversary of the effective date
of the Registration Statement. 
	 Company Obligations.  During the Registration Period, the Company
shall: 

(a) at least five (5) business days before filing the Registration
Statement or prospectus and at least three (3) business days before filing any
amendment thereto, the Company shall furnish to Celera's counsel copies of all
documents proposed to be filed for that counsel's review and approval, which
approval shall not be unreasonably withheld or delayed. 

(b)  furnish to Celera such reasonable number of copies of the
Registration Statement, each amendment and supplement thereto (including all
exhibits), the corresponding prospectus and preliminary prospectus, and such
other documents as Celera may reasonably request to facilitate the public sale
or other disposition of all or any of the Shares by Celera; provided,
however, that the obligation of the Company to deliver copies of
prospectuses or preliminary prospectuses to Celera shall be subject to Celera's
compliance with its covenants contained in Section 7.4(c) below; 

(c)promptly notify Celera of any stop order threatened or issued by
the SEC and shall use its commercially reasonable efforts to prevent the entry
of a stop order or if entered, to have it rescinded or otherwise removed; 

(d)use its commercially reasonable efforts to register or qualify the
Shares under such securities or blue sky laws of jurisdictions in the United
States as Celera reasonably requests and do any and all other reasonable acts
and things that may be necessary or advisable to enable Celera to consummate the
disposition of its Shares pursuant to the Registration Statement in such
jurisdiction; provided, however, that the Company shall not be
obligated to qualify as a foreign corporation to do business under the laws of
any jurisdiction in which it is not then qualified or to file any general
consent to service of process in any jurisdiction where it is not now so
subject; 

(e)promptly notify (in writing) Celera, at any time when a prospectus
is required to be delivered under the Securities Act, of the occurrence of any
event as a result of which the prospectus, as amended or supplemented, or any
document incorporated therein by reference contains an untrue statement of a
material fact or omits to state any material fact necessary to make the
statements therein not misleading in light of the circumstances under which such
statements were made and, except as permitted pursuant to the
"blackout" provisions of Section 7.5 hereof, prepare a supplement or
amendment to the prospectus or any such document incorporated therein so that
thereafter the prospectus will not contain an untrue statement of a material
fact or omit to state any material fact necessary to make the statements therein
not misleading in light of the circumstances under which such statements were
made; 

(e)use its commercially reasonable efforts to otherwise comply with
all applicable provisions of the Securities Act, the Exchange Act and related
rules and regulations of the SEC, and state securities or blue sky laws and
regulations; 

(f)use its commercially reasonable efforts to cause the Shares to be
listed on each securities exchange, if any, on which similar securities issued
by the Company are then listed, or cause the Shares to be authorized for trading
on NASDAQ, as the case may be; and 

(g)take all other steps reasonably necessary to effect the
registration and resale of the Shares contemplated hereby in accordance with the
terms of this Agreement. 

	 Registration Expenses.  All fees, disbursements and out-of-pocket
expenses and costs incurred by the Company in connection with the preparation
and filing of the Registration Statement pursuant to this Section 7 (including,
without limitation, all fees of the Company's counsel and independent auditors)
shall be borne by the Company.   All such fees and expenses incurred by Celera
(including fees of counsel to Celera) shall be borne by Celera. 
	 Celera's Obligations.   Celera shall: 

(a) promptly furnish to the Company in writing such information as the
Company reasonably requests regarding Celera and the Shares for use in
connection with such Registration Statement or the prospectus included therein,
including any amendment or supplement thereto; Celera shall promptly notify the
Company if any fact occurs with respect to the such information furnished to the
Company for inclusion in the Registration Statement and the prospectus, as
amended or supplemented, which results in the Registration Statement or the
prospectus, as amended or supplemented, containing an untrue statement of
material fact with respect to such information or omitting to state a material
fact with respect to such information required to be stated therein or necessary
to make the statements therein with respect to such information not misleading,
and shall provide to the Company such information as shall be necessary to
enable the Company to prepare a supplement or post-effective amendment to such
Registration Statement and prospectus or any document incorporated therein by
reference or file any other document required so that the Registration Statement
and prospectus, as amended or supplemented, will not contain an untrue statement
of a material fact with respect to such information or omit to state a material
fact with respect to such information required to be stated therein or necessary
to make the statements therein with respect to such information not misleading;

(b)upon receipt of any notice from the Company of any event of the
kind described in Section 7.2(e), will discontinue disposition of Shares
pursuant to the Registration Statement until it receives copies of the
supplemented or amended prospectus contemplated by Section 7.2(e).  In addition,
if the Company requests, Celera will deliver to the Company or destroy all
copies, other than permanent file copies then in Celera's possession, of the
prospectus covering the Shares current at the time of receipt of the notice; and

(c)(i) comply with all prospectus delivery requirements of the
Securities Act and applicable state securities or blue sky laws, and with all
anti-stabilization, anti-manipulation and similar provisions of Section 10 of
the Exchange Act and any rules issued thereunder by the SEC, (ii) sell or
dispose of the Shares in the manner described in the plan of distribution
section of the prospectus, as amended or supplemented, (iii) furnish to the
Company information about sales made in such public offering, and (iv) at the
end of the Registration Period, discontinue sales of shares pursuant to the
Registration Statement and advise the Company of the number of Shares remaining
unsold. 

	Blackout Period.  If (a) there is material non-public information
regarding the Company which the Company's Board of Directors (the
"Board") reasonably determines not to be in the Company's best
interest to disclose at such time, or (b) there is a significant business
opportunity (including, but not limited to, the acquisition or disposition of
assets (other than in the ordinary course of business) or any merger,
consolidation, tender offer or other similar transaction) available to the
Company which the Board reasonably determines not to be in the Company's best
interest to disclose at such time and which the Company would be required to
disclose under the Registration Statement, then the Company may suspend
effectiveness of the Registration Statement and suspend the sale of Shares under
the Registration Statement for a period not to exceed thirty (30) consecutive
days, provided that the Company may not suspend such obligations under
this Section 7.5 for more than ninety (90) days in the aggregate during any
twelve (12) month period; and provided, further, that no such suspension shall
be permitted for consecutive thirty (30) day periods, arising out of the same
set of facts, circumstances or transactions.  In addition to the foregoing, the
Company may suspend effectiveness of the Registration Statement and suspend the
sale of Shares under the Registration Statement upon written notice to Celera
for a period not to exceed ninety (90) consecutive days following the date of
the final prospectus used in an underwritten public offering of the Company's
Common Stock; provided that the Company may not provide more than one
notice of such suspension in any twelve (12) month period. 
	Indemnification.   (a) The Company agrees to indemnify and hold
harmless Celera, its officers, directors, employees, and agents, and each person
that controls Celera within the meaning of the Securities Act and the Exchange
Act, against all losses, claims, damages, liabilities and expenses caused by any
untrue or allegedly untrue statement of material fact contained in the
Registration Statement, any prospectus or preliminary prospectus contained
therein, or any omission or alleged omission to state a material fact required
to be stated therein or necessary to make the statements therein not misleading
in light of the circumstances under which such statements were made;
except to the extent the untrue or allegedly untrue statement or omission
or alleged omission resulted from information submitted by or on behalf of
Celera in writing to the Company expressly for use in the Registration
Statement; and provided, that with respect to any amended or supplemented
prospectus, the foregoing agreement to indemnify shall not apply or inure to the
benefit of Celera from whom the person asserting any loss, claim, damage,
liability or expense purchased Shares, if copies of an amended or supplemented
prospectus were delivered in a timely manner to the Celera pursuant to this
Agreement and a copy of the prospectus (as then amended or supplemented if the
Company shall have furnished any amendment or supplements thereto) was not sent
or given by or on behalf of Celera to such person, if required by law so to have
been delivered, and if the prospectus (as so amended or supplemented) would have
cured the defect giving rise to such loss, claim, damage, liability or expense. 

(b)  Celera agrees to indemnify the Company, its officers, directors,
employees, and agents, and each person that controls the Company within the
meaning of the Securities Act and the Exchange Act, against all losses, claims,
damages, liabilities and expenses resulting from (i) any failure to comply with
the covenants and agreements contained in Section 7.5 hereof, or (ii) any untrue
or allegedly untrue statement of a material fact or any omission or alleged
omission to state a material fact required to be stated in the registration
statement or prospectus or any amendment thereof or supplement thereto necessary
to make the statements therein not misleading in light of the circumstances
under which such statements were made, but only to the extent that the untrue or
allegedly untrue statement or omission or alleged omission is contained in or
omitted from any information submitted by or on behalf of Celera in writing to
the Company expressly for use in the Registration Statement, prospectus, or any
prospectus supplement, and (b) only in an amount not exceeding the proceeds
actually received by Celera with respect to Shares sold pursuant to the
Registration Statement, unless such liability resulted from gross negligence or
willful misconduct by Celera. 

(c)Any person entitled to indemnification under this Agreement shall
(i) give prompt notice to the indemnifying party of any claim with respect to
which it seeks indemnification, and (ii) unless the indemnified party shall have
been advised by counsel that a conflict of interest is likely to exist between
the indemnified and indemnifying parties with respect to the claim, permit the
indemnifying party to assume the defense of the claim with counsel reasonably
satisfactory to the indemnified party (in which event the indemnifying party
shall not be responsible for the fees and expenses of any separate counsel
employed by the indemnified party).  If the indemnifying party does not assume
the defense, the indemnifying party will not be liable for any settlement made
without its consent (but that consent may not be unreasonably withheld).  No
indemnifying party will consent to entry of any judgment or will enter into any
settlement (I) that does not include as an unconditional term thereof the
claimant's or plaintiff's release of the indemnified party from all liability
concerning the claim or litigation, or (II) that contains any admission of guilt
on the part of any indemnified party.  An indemnifying party who is not entitled
to or elects not to assume the defense of a claim will not be under an
obligation to pay the fees and expenses of more than one counsel in each
applicable jurisdiction for all parties indemnified by the indemnifying party
with respect to the claim, unless the indemnified party shall have been advised
by counsel that a conflict of interest is likely to exist between the
indemnified party and any other indemnified party with respect to the claim, in
which event the indemnifying party shall be obligated to pay the fees and
expenses of no more than one additional counsel for the indemnified parties.

(d)  If the indemnification provided for in this Section 7.6 is
unavailable to an indemnified party in respect of any losses, claims, damages,
liabilities or expenses referred to therein, then each indemnifying party
thereunder shall contribute to the amount paid or payable by such indemnified
party as a result of such losses, claims, damages, liabilities or expenses in
such proportion as is appropriate to reflect the relative fault of the Company
and Celera in connection with the statements or omissions that resulted in such
losses, claims, damages, liabilities or expenses, as well as any other relevant
equitable considerations.  The relative fault of the Company and Celera shall be
determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company or by Celera and
the parties' relative intent, knowledge, and opportunity to correct the untrue
or alleged untrue statement of a material fact or the omission or alleged
omission to state a material fact.  The amount paid or payable by an indemnified
party as a result of the losses, claims, damages, liabilities, and expenses
referred to in this Section 7.6 will be deemed to include, subject to the
limitations set forth in Section 7.6(c), any reasonable legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. 

The parties hereto agree that it would not be just and equitable if
contribution pursuant this Section 7.6(d) were determined by pro rata allocation
or by any other method of allocation that does not take account of the equitable
considerations referred to in the immediately preceding paragraph.
Notwithstanding anything herein to the contrary, Celera shall not be required to
contribute any amount in excess of the amount by which the proceeds actually
received by Celera from the sale of the Shares pursuant to the Registration
Statement exceeds the amount of any damages that Celera has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission.  No person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent
misrepresentation. 

(e)The indemnification and contribution provided for in this Section
7.6 will remain in full force and effect regardless of any investigation made by
or on behalf of the indemnified parties or any officer, director, employee,
agent or controlling person of the indemnified parties. 

 

	Conditions to Closing of Celera.  Celera's obligations to acquire the
Shares at the Closing are, at the option of Celera, subject to the truthfulness
of the Company's representations and warranties set forth in Section 3 hereof as
of the date of execution and delivery of this Agreement, and also as of the
Closing as if made on and as of the Closing date. In addition, the Company shall
deliver to Celera a certificate executed by its Chief Executive Officer
confirming the matters set forth in the preceding sentence without qualification
or exception. 

 

	Conditions to Closing of the Company.  The Company's obligations to
issue the Shares at the Closing are, at the option of the Company, subject to
the truthfulness of the Celera's representations and warranties set forth in
Section 4 hereof as of the date of execution and delivery of this Agreement, and
also as of the Closing as if made on and as of the Closing date.  In addition,
Celera shall deliver to the Company a certificate executed by its Chief
Executive Officer confirming the matters set forth in the preceding sentence
without qualification or exception. 

 

	Miscellaneous. 

	Further Assurances. Consistent with the terms and conditions hereof,
each party hereto will cooperate with each other and execute and deliver any and
all instruments and take any and all other actions, either before or after the
Closing, which may be necessary, proper, or advisable to effect or evidence the
provisions of this Agreement and to consummate the transactions contemplated
hereby. 
	Governing Law.  This Agreement and all acts and transactions pursuant
hereto and the rights and obligations of the parties hereto shall be governed,
construed and interpreted in accordance with the laws of the State of
California, without giving effect to its principles of conflicts of law or
choice of law. 
	Survival.  The representations and warranties contained herein shall
survive the execution and delivery of this Agreement and the sale of the Shares.

	Successors and Assigns.  The terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and
assigns of the parties as are permitted by this Agreement, provided that in the
event of any permitted sale or other transfer or disposition of shares under
this Agreement, the party acquiring such Shares shall hold such Shares free and
clear of the restrictions and without any of the rights contained in this
Agreement.  Nothing in this Agreement, express or implied, is intended to confer
upon any party other than the parties hereto or their respective successors and
permitted assigns any rights, remedies, obligations, or liabilities under
or by reason of this Agreement, except as expressly provided in this Agreement.

	Entire Agreement.  This Agreement and the Assignment Agreement embody
the entire understanding and agreement between Celera and the Company regarding
the subject matter hereto and thereto, and supersede all prior agreements and
understandings relating to the subject matter hereof and thereof. 
	Counterparts.  This Agreement may be executed in any number of
counterparts and signatures and may be delivered by facsimile, each of which
shall be enforceable against the parties actually executing such counterparts,
and all of which together shall constitute one instrument. 
	Expenses.  The Company and Celera shall each bear their own legal and
other expenses in connection with the transactions contemplated hereby. 
	Notices, Etc.  All notices and other communications required or
permitted hereunder shall be effective upon receipt and shall be in writing and
may be delivered in person, by telecopy, electronic mail, overnight delivery
service or U.S. mail, addressed (a) if to Celera, at its address set forth on
the signature page of this Agreement, or at such other address as Celera shall
have furnished the Company in writing, or (b) if to the Company, at the address
of its principal office, or at such other address as the Company shall have
furnished to Celera in writing. 
	California Corporate Securities Law.  THE SALE OF THE SECURITIES
WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR
PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT
FROM THE QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE.  THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.

	Titles and Subtitles.  The titles of the paragraphs and subparagraphs
of this Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
	Amendments and Waivers.  Any term of this Agreement may be amended or
waived (either generally or in a particular instance and either retroactively or
prospectively) only with the written consent of the Company and Celera.  Any
amendment or waiver effected in accordance with this Section 10.11 shall be
binding upon Celera, each transferee or future holder of the Shares and the
Company. 
	Severability.  If one or more provisions of this Agreement are held
to be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith.  In the event that the parties cannot reach a mutually
agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and
(c) the balance of the Agreement shall be enforceable in accordance with
its terms. 
	Adjustment of the Shares For Stock Splits, etc.  For purposes of this
Agreement, the term "Shares" shall include (a) any and all
shares of capital stock of the Company into which Shares are converted,
exchanged or substituted in any recapitalization or other capital reorganization
by the Company and (b) any and all equity securities of the Company or any
successor or assign of the Company which may be issued in respect of the Shares,
whether by conversion of, in exchange for or in substitution of, or as a
dividend on or distribution in respect of, such Shares.  The Shares shall be
deemed appropriately adjusted for any stock dividends, stock splits, reverse
stock splits, combinations, recapitalization and the like occurring after the
date of the Closing. 

(Signature Page Follows)

[ *** ] Indicates that material has been omitted and confidential treatment
has been requested therefor. 
 All such omitted material has been filed
separately with the Commission pursuant to Rule 24b-2. 

The parties have executed this Stock Purchase Agreement as of the date first
written above. 

	
COMPANY:
	 	CELERA:

	
PHARMACYCLICS, INC.
	
	APPLERA CORPORATION

THROUGH THE CELERA GENOMICS GROUP

	
/s/   RICHARD A. MILLER, M.D.  

______________________________

Name:  Richard A. Miller, M.D.

Title:  President and Chief Executive Officer
	 	/s/   KATHY P. ORDOÑEZ  

______________________________

Name:Kathy P. Ordoñez

Title:Senior Vice President and President,

Celera Genomics Group

	
Address: 995 E. Arques Avenue

Sunnyvale, CA  94085-4521
	 	Address:  1401 Harbor Bay Parkway

Alameda, CA 94502

	
With a copy of notices to:

Chief Financial Officer

Pharmacyclics, Inc. 

995 E. Arques Avenue

Sunnyvale, CA  94085-4521
	 	With a copy of notices to:

Secretary

Applera Corporation

301 Merritt 7

Norwalk, Ct  06851

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]